Drugs / anti-EGFRvIII CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02844062 | Jul 2016 → Jul 2018 | glioblastoma | Beijing Sanbo Brain Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-EGFRvIII CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02844062 ↗ |
| Modality | Cell therapy | “CAR T cell therapy” NCT02844062 ↗ |
| Route | Intravenous | “CAR T cells are infused intravenously to patients” NCT02844062 ↗ |
| Target | EGFR | “EGFRvIII is an attractive target for CAR T cell therapy.” NCT02844062 ↗ |